

Table S1. Competition of ACE2 binding compounds determined by Molecular docking and SPR screening of drug libraries with immobilised virus like particles (VLPs) expressing SARS-CoV2 Spike protein.

Name	K _D [nM] ^a	1:1 Competition between compound vs CoV2 VLP
Evans Blue	1.63±0.08	98.9% ± 6.43
Levodopa	13.6±0.97	42.1% ± 5.17
Epigallocatechin-3-gallate	13.7±1.90	33.8% ± 4.67
Velpatasvir	24.9±4.24	68.1% ± 9.44
Acalabrutinib	25.7±0.91	81.2% ± 12.9
Venetoclax	290±31.1	69.1% ± 7.31
Chicago Sky Blue	349±29.8	7.29% ± 1.64
Ledipasvir	417±50.7	84.9% ± 7.3
Irinotecan	825±112	100% ± 9.17
Digitoxin	1480±87.6	23.6% ± 4.25
Digoxin	1254±97.2	31.5% ± 4.55
Zotarolimus	2764±178	71.6% ± 6.47
Immobilized SARS-CoV2 Spike protein VLP vs flowed ACE2	43.1±7.4	N/A

^aK_D determined by SPR.